Agios Pharmaceuticals (AGIO) Cash from Discontinued Operations (2020 - 2021)

Agios Pharmaceuticals (AGIO) reported Cash from Discontinued Operations of 4102000.0 for Q4 2021, down 335.48% on a YoY basis from 1742000.0 in Q4 2020, and up 60.24% quarter-over-quarter from 10318000.0 in Q3 2021.

Agios Pharmaceuticals (AGIO) Cash from Discontinued Operations (2020 - 2021) Analysis & Trends

Agios Pharmaceuticals has reported Cash from Discontinued Operations for 2 years, with the latest figure at 4102000.0 in Q4 2021.

  • For the quarter ending Q4 2021, Cash from Discontinued Operations fell 335.48% year-over-year to 4102000.0; the trailing twelve-month figure through Sep 2022 stood at 4102000.0 (up 95.31% YoY), and the FY2021 full-year result was 93234000.0, down 99.15% from the prior year.
  • Cash from Discontinued Operations for Q4 2021 stood at 4102000.0, up from 10318000.0 in the prior quarter.
  • The five-year high for Cash from Discontinued Operations was 1742000.0 in Q4 2020, with the low at 48291000.0 in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -59.14 Mn
10 Agios Pharmaceuticals 2.01 Bn 2.01 Bn 19.43 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2021 -4.10 Mn
Dec 31, 2021 -4.10 Mn
Sep 30, 2021 -10.32 Mn
Sep 30, 2021 -10.32 Mn
Jun 30, 2021 -48.29 Mn
Jun 30, 2021 -48.29 Mn
Mar 31, 2021 -30.52 Mn
Mar 31, 2021 -30.52 Mn
Dec 31, 2020 1.74 Mn
Dec 31, 2020 1.74 Mn
Sep 30, 2020 -11.59 Mn
Sep 30, 2020 -11.59 Mn
Jun 30, 2020 -10.39 Mn
Jun 30, 2020 -10.39 Mn
Mar 31, 2020 -26.58 Mn
Mar 31, 2020 -26.58 Mn